Tafasitamab Mechanism of Action

ADCC:Antibody-dependent cell-mediated cytotoxicity
ADCP:Antibody-dependent cellular phagocytosis

Clinical Data

The result of a five-year study from L-MIND shows that tafasitamab provided prolonged, durable responses in patients
with relapsed or refractory DLBCL.
57.5% ORR
The ORR was 57.5%, with CR of 41.3% and PR of 16.2%.
41.3% CR
16.2% PR
Additional results include:
• Median duration of response (DoR) was not reached after a median follow up of 44.0 months.
• The median overall survival was 33.5 months and median progression-free survival was 11.6 months.
• Patients with one pLoT (n = 40) had a higher ORR of 67.5% (CR = 52.5% and PR = 15%).

Benefits for Patients

DLBCL is a prevalent type of NHL in China, accounting for 45.8% of all cases, with approximately 60,000 new patients annually. Following first-line treatment, 30%–40% of patients will develop relapsed or refractory disease. More than half of patients are ineligible for salvage chemotherapy and autologous hematopoietic stem cell transplantation. The approval of tafasitamab offers a safer and more effective targeted treatment option for these patients.